BDTX: 54% | Black Diamond Therapeutics shares are trading higher after the company announced initial Phase 2 data demonstrating encouraging clinical responses and durability of BDTX-1535 in patients with relapsed/refractory epidermal growth factor receptor-mutant non-small cell lung cancer.

VTYX: 42% | Ventyx Biosciences Announces Sanofi Has Agreed To Make A $27M Investment In Co. At An As-Converted Price Of $3.8243 Per Share, Pursuant To Which Sanofi Will Purchase 70,601 Shares Of Series A Non-Voting Convertible Preferred Stock

BHVN: 26% | Biohaven shares are trading higher after the company announced its study of Troriluzole for the treatment of spinocerebellar ataxia in achieved the primary endpoint.